AZIYO BIOLOGICS INC-CLASS A (AZYO) Fundamental Analysis & Valuation
NASDAQ:AZYO • US05479K1060
Current stock price
1.49 USD
+0.03 (+2.05%)
Last:
This AZYO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AZYO Profitability Analysis
1.1 Basic Checks
- AZYO had negative earnings in the past year.
- In the past year AZYO has reported a negative cash flow from operations.
1.2 Ratios
- The profitability ratios for AZYO are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 35.86%, AZYO is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
- In the last couple of years the Gross Margin of AZYO has declined.
- AZYO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
2. AZYO Health Analysis
2.1 Basic Checks
- AZYO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for AZYO has been increased compared to 1 year ago.
- AZYO has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -4.75, we must say that AZYO is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of AZYO (-4.75) is worse than 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.75 |
ROIC/WACCN/A
WACC16.57%
2.3 Liquidity
- AZYO has a Current Ratio of 0.84. This is a bad value and indicates that AZYO is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 0.84, AZYO is doing worse than 92.99% of the companies in the same industry.
- AZYO has a Quick Ratio of 0.84. This is a bad value and indicates that AZYO is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of AZYO (0.63) is worse than 94.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.63 |
3. AZYO Growth Analysis
3.1 Past
- AZYO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.95%, which is quite impressive.
- AZYO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.13%.
- Measured over the past years, AZYO shows a small growth in Revenue. The Revenue has been growing by 4.66% on average per year.
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%
3.2 Future
- AZYO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
- AZYO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.27% yearly.
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. AZYO Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for AZYO. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AZYO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AZYO's earnings are expected to grow with 17.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3YN/A
5. AZYO Dividend Analysis
5.1 Amount
- AZYO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AZYO Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:AZYO (9/6/2023, 8:00:01 PM)
1.49
+0.03 (+2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners74.28%
Inst Owner Change-12.26%
Ins Owners3.94%
Ins Owner Change0%
Market Cap24.21M
Revenue(TTM)48.40M
Net Income(TTM)-33.95M
Analysts82.86
Price Target8.16 (447.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.35%
Min EPS beat(2)-119.74%
Max EPS beat(2)11.04%
EPS beat(4)2
Avg EPS beat(4)-17.6%
Min EPS beat(4)-119.74%
Max EPS beat(4)46.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.93%
Min Revenue beat(2)-19.25%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-7.19%
Min Revenue beat(4)-19.25%
Max Revenue beat(4)-1.06%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-133.33%
EPS NQ rev (3m)-55.56%
EPS NY rev (1m)-76.03%
EPS NY rev (3m)-33.12%
Revenue NQ rev (1m)48.44%
Revenue NQ rev (3m)-36.24%
Revenue NY rev (1m)12.37%
Revenue NY rev (3m)-27.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS2.98
BVpS-1.36
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.86% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
F-Score3
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.74% | ||
| Cap/Sales | 1.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.63 | ||
| Altman-Z | -4.75 |
F-Score3
WACC16.57%
ROIC/WACCN/A
Cap/Depr(3y)13.65%
Cap/Depr(5y)12.19%
Cap/Sales(3y)1.13%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.81%
OCF growth 3YN/A
OCF growth 5YN/A
AZIYO BIOLOGICS INC-CLASS A / AZYO Fundamental Analysis FAQ
What is the fundamental rating for AZYO stock?
ChartMill assigns a fundamental rating of 1 / 10 to AZYO.
What is the valuation status for AZYO stock?
ChartMill assigns a valuation rating of 1 / 10 to AZIYO BIOLOGICS INC-CLASS A (AZYO). This can be considered as Overvalued.
How profitable is AZIYO BIOLOGICS INC-CLASS A (AZYO) stock?
AZIYO BIOLOGICS INC-CLASS A (AZYO) has a profitability rating of 1 / 10.
What is the financial health of AZIYO BIOLOGICS INC-CLASS A (AZYO) stock?
The financial health rating of AZIYO BIOLOGICS INC-CLASS A (AZYO) is 0 / 10.
What is the earnings growth outlook for AZIYO BIOLOGICS INC-CLASS A?
The Earnings per Share (EPS) of AZIYO BIOLOGICS INC-CLASS A (AZYO) is expected to grow by 9.47% in the next year.